| Peer-Reviewed

Benign Prostatic Hyperplasia: Evaluation of Predictive Factors of the Outcome of the Catheter Ablation Test After Afluzosin Treatment in a Senegalese University Hospital

Received: 17 June 2023    Accepted: 4 July 2023    Published: 11 July 2023
Views:       Downloads:
Abstract

Introduction: The use of alpha-blockers facilitates catheter ablation testing (CAT) in patients with benign prostatic hyperplasia (BPH) complicated by complete retention of urine. The aim of our study was to determine the predictive factors for failure of CAT in these patients. Patients and Method: This was a single-centre prospective study conducted at the Urology Department of Aristide Le Dantec Hospital in Dakar from January 1st 2021 December 31st 2021. The parameters studied were: age, digital rectal examination, PSA, CBEU, prostate biopsy, ultrasound and therapeutic results. We tried to determine the factors associated with failure of the urinary catheter removal test. Results: The mean age of the patients was 67.9 +/- 9.2 years (44-93 years). The mean prostate volume was 89.7 ml +/- 42.5. A median lobe was observed in 27.6% of patients. The success rate was higher in the first than in the second CAT (34.2% vs 6%). A higher failure rate was observed (68.9% vs 33.3%) in patients with a PSA > 4 ng/ml (p=0.01). Patients with a prostate volume > 80 ml had a significantly higher failure rate (77.5%) (p<0.01). The failure rate on CAT was higher (p=0.03) in patients who had a median lobe on suprapubic ultrasound (36.2% vs 13.8%). Conclusions: PSA level (threshold  4 ng/ml); prostate volume (80 ml); presence of a median lobe were predictive factors of CAT failure. We found no interest in performing a second CAT.

Published in International Journal of Clinical Urology (Volume 7, Issue 2)
DOI 10.11648/j.ijcu.20230702.11
Page(s) 29-33
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Prostate, BPH, Bladder Retention, Alfuzosin, Senegal

References
[1] Billet M, Windsor TA. Urinary Retention. Emerg Med Clin N Am 2019; 37 : 649-660.
[2] Diallo AB, Bah I, Diallo T, Bah O, Amougou B, Bah M, et al. Le profil des urgences urologiques au CHU de Conakry, Guinée. Progrès en urologie. 2010; 20 (3): 214-8.
[3] Bengtsen MB, Heide-Jørgensen U, Blichert-Refsgaard LS, Hjelholt TJ, Borre M, Nørgaard M. Positive predictive value of benign prostatic hyperplasia and acute urinary retention in the danish national patient registry: A validation study. Clinical Epidemiology. 2020; 1281-5.
[4] Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia–what do we know? BJU international. 2021; 127 (4): 389-99.
[5] Nickel JC, Aaron L, Barkin J, Elterman D, Nachabé M, Zorn KC. Guide de pratique de l’Association des urologues du Canada sur les symptômes du bas appareil urinaire chez l’homme et l’hyperplasie bénigne de la prostate (SBAUH/HBP): mise à jour de 2018. CUAJ. 2018; 12 (10): R91.
[6] Jardin A, Bensadoun H, Delauche–Cavallier M, Stalla–Bourdillon A, Group PAB. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey. British journal of urology. 1994; 74 (5): 579-84.
[7] Patil SB, Ranka K, Kundargi VS, Guru N. Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study. Central European Journal of Urology. 2017; 70 (3): 259.
[8] Descazeaud A, Delongchamps NB, Cornu JN, Azzouzi A, Buchon D, Benchikh A, et al. Guide de prise en charge en médecine générale des symptômes du bas appareil urinaire de l’homme liés à une hyperplasie bénigne de la prostate. Progrès en urologie. 2015; 25 (7): 404-12.
[9] Caine M, PFAU A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. British journal of urology. 1976; 48 (3): 255-63.
[10] Desgrandchamps F, De La Taille A, Doublet J, RetenFrance Study Group. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU international. 2006; 97 (4): 727-33.
[11] Bastien L, Fourcade R, Makhoul B, Meria P. Hyperplasie bénigne de la prostate. EMC. Elsevier Masson SAS, Paris) Urologie. 2011; 22: 14-29.
[12] Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Reviews in urology. 2001; 3 (4): 187.
[13] Hastie K, Dickinson A, Ahmad R, Moisey C. Acute retention of urine: is trial without catheter justified? Journal of the Royal College of Surgeons of Edinburgh. 1990; 35 (4): 225-7.
[14] McNeill S, Hargreave T, Alfaur Study Group. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. The Journal of urology. 2004; 171 (6 Part 1): 2316-20.
[15] Fowler Jr JE, Bigler SA, Kilambi NK, Land SA. Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies. Urology. 1999; 53 (6): 1175-8.
[16] Bansal A, Arora A. Predictors of successful trial without catheter following acute urinary retention in benign prostatic enlargement: A single centre, multivariate analysis. Neurourology and urodynamics. 2017; 36 (7): 1757-62.
[17] Jha AA, Singh G, Govindaiah M, Solanki N. Predictors of successful trial with-out catheter following acute urinary retention secondary to benign prostatic hypertrophy. International Surgery Journal. 23 oct 2020; 7 (11): 3718-23. 18.
[18] Fitzpatrick JM, Desgrandchamps F, Adjali K, Guerra LG, Hong SJ, Khalid SE, et al. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU international. 2012; 109 (1): 88-95.
[19] Lebdai S, Ammi M, Bigot P, Cornu JN, Mathieu R, Descazeaud A, et al. Impact en pratique clinique de l’indice de protrusion prostatique intravésicale: une revue de la littérature du CTMH de l’AFU. Progrès en urologie. 2014; 24 (5): 313-8.
[20] Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology. 1999; 53 (3): 473-80.
[21] Speakman MJ. Prostate-specific antigen: could it be a useful marker for bladder outlet obstruction? european urology. 2008; 54 (6): 1223-5.
[22] Cahn DB, Ross CP, Dubowitch EP, Persun ML, Ginsberg PC, Harkaway RC. Predicting Acute Urinary Retention in Patients with Elevated Post-Void Residuals. Current Urology. 2014; 8 (2): 79-83.
[23] Lim K, Wong M, Foo K. The outcome of trial off catheter after acute retention of urine. Annals of the Academy of Medicine, Singapore. 1999; 28 (4): 516-8.
[24] Zeif HJ, Wallace DMA, Subramonian K. Predictors of successful trial without catheter in acute urinary retention. British Journal of Medical and Surgical Urology. 2010; 3 (1): 5-10.
[25] Tiong H, Tibung M, Macalalag M, Li M, Consigliere D. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis. 2009; 83 (1): 44-8.
[26] Mariappan P, Brown DJ, McNeill AS. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study. The Journal of urology. 2007; 178 (2): 573-7.
[27] Hagiwara K, Koie T, Iwamura H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Ohyama C. Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study. Biomed Res Int. 2016; 2016: 4975851. doi: 10.1155/2016/4975851. Epub 2016 Apr 18. PMID: 27195288; PMCID.
Cite This Article
  • APA Style

    Cyrille Ze Ondo, Ndiaga Seck Ndour, Ousmane Sow, Amath Thiam, Alioune Sarr, et al. (2023). Benign Prostatic Hyperplasia: Evaluation of Predictive Factors of the Outcome of the Catheter Ablation Test After Afluzosin Treatment in a Senegalese University Hospital. International Journal of Clinical Urology, 7(2), 29-33. https://doi.org/10.11648/j.ijcu.20230702.11

    Copy | Download

    ACS Style

    Cyrille Ze Ondo; Ndiaga Seck Ndour; Ousmane Sow; Amath Thiam; Alioune Sarr, et al. Benign Prostatic Hyperplasia: Evaluation of Predictive Factors of the Outcome of the Catheter Ablation Test After Afluzosin Treatment in a Senegalese University Hospital. Int. J. Clin. Urol. 2023, 7(2), 29-33. doi: 10.11648/j.ijcu.20230702.11

    Copy | Download

    AMA Style

    Cyrille Ze Ondo, Ndiaga Seck Ndour, Ousmane Sow, Amath Thiam, Alioune Sarr, et al. Benign Prostatic Hyperplasia: Evaluation of Predictive Factors of the Outcome of the Catheter Ablation Test After Afluzosin Treatment in a Senegalese University Hospital. Int J Clin Urol. 2023;7(2):29-33. doi: 10.11648/j.ijcu.20230702.11

    Copy | Download

  • @article{10.11648/j.ijcu.20230702.11,
      author = {Cyrille Ze Ondo and Ndiaga Seck Ndour and Ousmane Sow and Amath Thiam and Alioune Sarr and Abdoulaye Ndiath and Adaito Bermendora and Babacar Sine and Modou Ndiaye and El Hadj Malick Diaw and Babacar Diao and Alain Khassim Ndoye},
      title = {Benign Prostatic Hyperplasia: Evaluation of Predictive Factors of the Outcome of the Catheter Ablation Test After Afluzosin Treatment in a Senegalese University Hospital},
      journal = {International Journal of Clinical Urology},
      volume = {7},
      number = {2},
      pages = {29-33},
      doi = {10.11648/j.ijcu.20230702.11},
      url = {https://doi.org/10.11648/j.ijcu.20230702.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20230702.11},
      abstract = {Introduction: The use of alpha-blockers facilitates catheter ablation testing (CAT) in patients with benign prostatic hyperplasia (BPH) complicated by complete retention of urine. The aim of our study was to determine the predictive factors for failure of CAT in these patients. Patients and Method: This was a single-centre prospective study conducted at the Urology Department of Aristide Le Dantec Hospital in Dakar from January 1st 2021 December 31st 2021. The parameters studied were: age, digital rectal examination, PSA, CBEU, prostate biopsy, ultrasound and therapeutic results. We tried to determine the factors associated with failure of the urinary catheter removal test. Results: The mean age of the patients was 67.9 +/- 9.2 years (44-93 years). The mean prostate volume was 89.7 ml +/- 42.5. A median lobe was observed in 27.6% of patients. The success rate was higher in the first than in the second CAT (34.2% vs 6%). A higher failure rate was observed (68.9% vs 33.3%) in patients with a PSA > 4 ng/ml (p=0.01). Patients with a prostate volume > 80 ml had a significantly higher failure rate (77.5%) (pConclusions: PSA level (threshold  4 ng/ml); prostate volume (80 ml); presence of a median lobe were predictive factors of CAT failure. We found no interest in performing a second CAT.},
     year = {2023}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Benign Prostatic Hyperplasia: Evaluation of Predictive Factors of the Outcome of the Catheter Ablation Test After Afluzosin Treatment in a Senegalese University Hospital
    AU  - Cyrille Ze Ondo
    AU  - Ndiaga Seck Ndour
    AU  - Ousmane Sow
    AU  - Amath Thiam
    AU  - Alioune Sarr
    AU  - Abdoulaye Ndiath
    AU  - Adaito Bermendora
    AU  - Babacar Sine
    AU  - Modou Ndiaye
    AU  - El Hadj Malick Diaw
    AU  - Babacar Diao
    AU  - Alain Khassim Ndoye
    Y1  - 2023/07/11
    PY  - 2023
    N1  - https://doi.org/10.11648/j.ijcu.20230702.11
    DO  - 10.11648/j.ijcu.20230702.11
    T2  - International Journal of Clinical Urology
    JF  - International Journal of Clinical Urology
    JO  - International Journal of Clinical Urology
    SP  - 29
    EP  - 33
    PB  - Science Publishing Group
    SN  - 2640-1355
    UR  - https://doi.org/10.11648/j.ijcu.20230702.11
    AB  - Introduction: The use of alpha-blockers facilitates catheter ablation testing (CAT) in patients with benign prostatic hyperplasia (BPH) complicated by complete retention of urine. The aim of our study was to determine the predictive factors for failure of CAT in these patients. Patients and Method: This was a single-centre prospective study conducted at the Urology Department of Aristide Le Dantec Hospital in Dakar from January 1st 2021 December 31st 2021. The parameters studied were: age, digital rectal examination, PSA, CBEU, prostate biopsy, ultrasound and therapeutic results. We tried to determine the factors associated with failure of the urinary catheter removal test. Results: The mean age of the patients was 67.9 +/- 9.2 years (44-93 years). The mean prostate volume was 89.7 ml +/- 42.5. A median lobe was observed in 27.6% of patients. The success rate was higher in the first than in the second CAT (34.2% vs 6%). A higher failure rate was observed (68.9% vs 33.3%) in patients with a PSA > 4 ng/ml (p=0.01). Patients with a prostate volume > 80 ml had a significantly higher failure rate (77.5%) (pConclusions: PSA level (threshold  4 ng/ml); prostate volume (80 ml); presence of a median lobe were predictive factors of CAT failure. We found no interest in performing a second CAT.
    VL  - 7
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, H?pital Militaire de Ouakam, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Department of Urology, Aristide Le Dantec Hospital, Dakar, Senegal

  • Sections